CFM
SRPT icon

Catalyst Funds Management’s Sarepta Therapeutics SRPT Stock Holding History

Catalyst Funds Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
14,200
-5,000
-26% -$94.6K 0.01% 530
2026
Q1 		$418K Buy
19,200
+9,700
+102% +$188K 0.07% 282
2025
Q4 		$204K Buy
+9,500
New +$200K 0.05% 292
2024
Q2 		– Sell
-1,200
Closed -$155K – 1570
2024
Q1 		$155K Buy
+1,200
New +$147K 0.04% 308

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Catalyst Funds Management's SRPT Position: Q2 2026 in Review

Catalyst Funds Management reduced its Sarepta Therapeutics (SRPT) stake by 26% in Q2 2026, selling an estimated $94.6K and leaving 14,200 shares worth $255K. The position accounts for 0.01% of the portfolio, ranked #530.

Catalyst Funds Management first reported a position in SRPT in Q1 2024 and has held it in 4 quarters since. The position peaked at $418K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Catalyst Funds Management held 14,200 shares of Sarepta Therapeutics worth $255K as of Q2 2026.
  • Catalyst Funds Management sold 5,000 Sarepta Therapeutics shares in Q2 2026, an estimated $94.6K.
  • Sarepta Therapeutics made up 0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #530 holding.
  • Catalyst Funds Management first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Catalyst Funds Management's Sarepta Therapeutics position peaked at $418K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.